PH12015500435A1 - Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions - Google Patents
Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditionsInfo
- Publication number
- PH12015500435A1 PH12015500435A1 PH12015500435A PH12015500435A PH12015500435A1 PH 12015500435 A1 PH12015500435 A1 PH 12015500435A1 PH 12015500435 A PH12015500435 A PH 12015500435A PH 12015500435 A PH12015500435 A PH 12015500435A PH 12015500435 A1 PH12015500435 A1 PH 12015500435A1
- Authority
- PH
- Philippines
- Prior art keywords
- constipation
- formulations
- alternative embodiments
- treating
- ameliorating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 206010010774 Constipation Diseases 0.000 title abstract 7
- 206010017943 Gastrointestinal conditions Diseases 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 239000008141 laxative Substances 0.000 title 1
- 230000002475 laxative effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 4
- -1 e.g. Substances 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 206010000060 Abdominal distension Diseases 0.000 abstract 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 2
- 206010071061 Small intestinal bacterial overgrowth Diseases 0.000 abstract 2
- 208000024330 bloating Diseases 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 2
- 230000007142 small intestinal bacterial overgrowth Effects 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010006326 Breath odour Diseases 0.000 abstract 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 abstract 1
- 206010013554 Diverticulum Diseases 0.000 abstract 1
- 208000032139 Halitosis Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000012868 Overgrowth Diseases 0.000 abstract 1
- 206010036772 Proctalgia Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 208000037902 enteropathy Diseases 0.000 abstract 1
- 206010016766 flatulence Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261694672P | 2012-08-29 | 2012-08-29 | |
| US201261723027P | 2012-11-06 | 2012-11-06 | |
| PCT/AU2013/000973 WO2014032108A1 (en) | 2012-08-29 | 2013-08-29 | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015500435A1 true PH12015500435A1 (en) | 2015-04-20 |
Family
ID=50182266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015500435A PH12015500435A1 (en) | 2012-08-29 | 2015-02-27 | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150216806A1 (enExample) |
| EP (1) | EP2890367A4 (enExample) |
| JP (1) | JP2015531770A (enExample) |
| KR (1) | KR20150046310A (enExample) |
| CN (1) | CN104936581A (enExample) |
| AU (1) | AU2013308403B2 (enExample) |
| BR (1) | BR112015004165A2 (enExample) |
| CA (1) | CA2882316A1 (enExample) |
| HK (1) | HK1212222A1 (enExample) |
| IL (1) | IL237276A0 (enExample) |
| IN (1) | IN2015DN01857A (enExample) |
| MX (1) | MX2015002210A (enExample) |
| PH (1) | PH12015500435A1 (enExample) |
| RU (1) | RU2015111258A (enExample) |
| WO (1) | WO2014032108A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011342368B2 (en) | 2010-12-13 | 2016-11-17 | Rite-Prep Pty Ltd | Gastric and colonic formulations and methods for making and using them |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
| JP6441890B2 (ja) | 2013-03-15 | 2018-12-19 | ブレインツリー・ラボラトリーズ，インコーポレイテッド | 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CA2910983C (en) * | 2013-04-30 | 2021-11-02 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
| WO2015084158A1 (en) * | 2013-12-06 | 2015-06-11 | N.V. Nutricia | A pyrimidine derivative and a fatty acid source for use in the treatment of constipation |
| US10105360B2 (en) * | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
| EP3079661B1 (de) | 2013-12-11 | 2021-05-05 | Algobate AG | Naloxon-monopräparat und mehrschichttablette |
| KR101420315B1 (ko) * | 2014-03-19 | 2014-07-17 | 남봉길 | 약학적 액제 조성물 |
| RO130546B1 (ro) * | 2014-04-28 | 2019-03-29 | Mariana Lisinschi | Unguent pentru tratamentul bolii hemoroidale |
| EP3137167A4 (en) | 2014-04-29 | 2017-12-20 | Colonaryconcepts LLC | Foods, systems, methods, and kits for providing electrolyte replacement |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| HK1247283A1 (zh) | 2015-03-02 | 2018-09-21 | 科罗纳里康赛普茨有限责任公司 | 用於peg代谢物及peg分解产物检测的化合物及方法 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| WO2016178578A1 (en) * | 2015-05-06 | 2016-11-10 | Polyvation B.V. | Antimicrobial compositions and methods for reducing microbial contamination |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| RU2018105869A (ru) | 2015-08-17 | 2019-09-19 | Ферринг Б.В. | Жидкие составы, содержащие пикосульфат и цитрат магния |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US20190000976A1 (en) * | 2016-01-28 | 2019-01-03 | Ctc Bio,Inc. | Purgative Composition |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN109475544A (zh) * | 2016-03-29 | 2019-03-15 | 科罗纳里康赛普茨有限责任公司 | 用于治疗便秘的制剂 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CN109906079B (zh) | 2016-06-16 | 2022-09-30 | 库蒂斯制药公司 | 用于质子泵抑制剂混悬剂的组合物和方法 |
| US20190298735A1 (en) * | 2016-07-08 | 2019-10-03 | Vanderbilt University | Treatment and prevention of clostridium difficile colitis using misoprostol |
| WO2018009761A1 (en) | 2016-07-08 | 2018-01-11 | Ferring B.V. | Stabilized liquid formulations containing picosulfate |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| CN106556666A (zh) * | 2016-11-02 | 2017-04-05 | 陕西嘉禾生物科技股份有限公司 | 一种欧鼠李皮和美鼠李皮的薄层鉴定方法 |
| IT201600122310A1 (it) | 2016-12-01 | 2018-06-01 | Sofar Spa | Composizione per uso nella terapia di alterazioni dell'intestino |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN106830417B (zh) * | 2017-01-12 | 2021-05-11 | 新宇药业股份有限公司 | 一种高效降解废水中林可霉素的处理方法 |
| CN107616984A (zh) * | 2017-01-13 | 2018-01-23 | 江苏西宏生物医药有限公司 | 一种抗腹泻的经肠营养组合物 |
| CN107616983A (zh) * | 2017-01-13 | 2018-01-23 | 江苏西宏生物医药有限公司 | 一种抗腹泻的经肠营养组合物 |
| CN107518411A (zh) * | 2017-01-13 | 2017-12-29 | 江苏西宏生物医药有限公司 | 一种抗腹泻的经肠营养组合物 |
| GB201704909D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
| RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| EP3737245A4 (en) * | 2018-01-12 | 2021-08-25 | Colonaryconcepts LLC | CONCENTRATED SOLID FORMULATIONS FOR CONSTIPATION TREATMENT |
| US20200383934A1 (en) * | 2018-01-12 | 2020-12-10 | Colonaryconcepts Llc | Constipation specific treatment formulations |
| CA3093970A1 (en) * | 2018-03-16 | 2019-09-19 | Anji Pharmaceuticals Inc. | Compositions and methods for treating severe constipation |
| CN110403945B (zh) * | 2018-04-28 | 2022-11-18 | 上海泽生科技开发股份有限公司 | 促进胃肠系统动力的复合维生素组合物及其制备方法 |
| CN115581699A (zh) * | 2018-04-28 | 2023-01-10 | 上海泽生科技开发股份有限公司 | 促进胃肠系统动力的复合维生素组合物及其制备方法 |
| CN108819052A (zh) * | 2018-05-04 | 2018-11-16 | 苏州捷德瑞精密机械有限公司 | 一种树脂基体系用脱模剂及其制备方法 |
| JP7421504B2 (ja) * | 2018-06-01 | 2024-01-24 | ビオラ・セラピューティクス・インコーポレイテッド | 胃腸のマイクロバイオームの検出および操作のためのデバイスおよびシステム |
| JP6661712B2 (ja) * | 2018-08-15 | 2020-03-11 | 旭化成ワッカーシリコーン株式会社 | シリコーン消泡剤組成物、および、シリコーン消泡剤組成物の製造方法。 |
| CN109394711A (zh) * | 2018-11-06 | 2019-03-01 | 威海贯标信息科技有限公司 | 一种酒石酸西尼必利片组合物 |
| CN109337098B (zh) * | 2018-11-23 | 2021-02-02 | 哈尔滨工程大学 | 一种酶响应型结肠靶向载药凝胶的制备方法 |
| CN109749960B (zh) * | 2019-01-31 | 2020-05-26 | 上海宝藤生物医药科技股份有限公司 | 基于多种肠道细菌含量评估便秘风险及便秘程度的方法及装置 |
| US10857092B2 (en) * | 2019-03-14 | 2020-12-08 | Glen D Lindbo | Avoiding gag reflex to enable swallowing pills |
| JP2022526495A (ja) * | 2019-03-18 | 2022-05-25 | シーダーズ－サイナイ・メディカル・センター | 胃腸疾患および障害を治療するための組成物およびその方法 |
| CN110051655A (zh) * | 2019-03-19 | 2019-07-26 | 吉林省盛赛医药实业有限公司 | 一种治疗便秘的复方制剂的制备方法 |
| US12053447B2 (en) | 2019-06-25 | 2024-08-06 | NuBioPharma, LLC | Oral solution and powder to liquid compositions of balsalazide |
| CN114364391B (zh) * | 2019-07-08 | 2023-08-11 | 吉亚生技控股股份有限公司 | 改善或抑制胃肠道不适的组合物及方法 |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| CN112386577B (zh) * | 2019-08-16 | 2024-01-23 | 北京天衡药物研究院有限公司 | 一种治疗便秘的组合物 |
| RU2716144C1 (ru) * | 2019-09-23 | 2020-03-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ консервативного лечения послеоперационного пареза кишечника у новорожденных детей |
| CN110833537B (zh) * | 2019-11-15 | 2021-04-13 | 三峡大学 | 药物缓释材料及其在制备治疗直肠炎的缓释材料上的应用 |
| CN111920798A (zh) * | 2020-06-24 | 2020-11-13 | 首都医科大学附属北京同仁医院 | 一种硝呋酚酰肼在制备药物中的应用 |
| CN112843077A (zh) * | 2020-09-08 | 2021-05-28 | 天津国际生物医药联合研究院 | 表柔比星或者硫酸博来霉素在抗分枝杆菌感染中的潜在应用 |
| CN112189761A (zh) * | 2020-10-30 | 2021-01-08 | 安佑生物科技集团股份有限公司 | 一种防治动物便秘的饲料添加剂及其制备方法和应用 |
| CN114869879B (zh) * | 2022-05-09 | 2024-06-25 | 南方医科大学珠江医院 | 一种具备活性氧和炎症双重抑制作用的小分子水凝胶及其制备方法 |
| CN114965764B (zh) * | 2022-05-18 | 2024-12-31 | 陕西安宁云生生物技术有限公司 | 便秘的诊断和治疗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA761927A (en) * | 1967-06-27 | Seeger Ernst | Benzoxazine derivatives | |
| MXPA01003197A (es) * | 1998-09-28 | 2004-04-21 | Warner Lambert Co | Suministro enterico y colonico utilizando capsulas de chpm. |
| CN1288730A (zh) * | 1999-09-07 | 2001-03-28 | 麦克内尔-Ppc股份有限公司 | 轻泻组合物 |
| EP1225897B1 (en) * | 1999-11-01 | 2004-09-08 | RHODES, John | Composition for treatment of constipation and irritable bowel syndrome |
| US6541025B1 (en) * | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| ES2645930T3 (es) * | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
| US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
| US20060229261A1 (en) * | 2005-04-12 | 2006-10-12 | John Devane | Acarbose methods and formulations for treating chronic constipation |
| US9161918B2 (en) * | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
| WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| AU2011342368B2 (en) * | 2010-12-13 | 2016-11-17 | Rite-Prep Pty Ltd | Gastric and colonic formulations and methods for making and using them |
-
2013
- 2013-08-29 JP JP2015528809A patent/JP2015531770A/ja active Pending
- 2013-08-29 BR BR112015004165A patent/BR112015004165A2/pt not_active Application Discontinuation
- 2013-08-29 EP EP13832124.5A patent/EP2890367A4/en not_active Withdrawn
- 2013-08-29 KR KR20157007861A patent/KR20150046310A/ko not_active Ceased
- 2013-08-29 WO PCT/AU2013/000973 patent/WO2014032108A1/en not_active Ceased
- 2013-08-29 AU AU2013308403A patent/AU2013308403B2/en not_active Ceased
- 2013-08-29 US US14/424,515 patent/US20150216806A1/en not_active Abandoned
- 2013-08-29 HK HK16100131.2A patent/HK1212222A1/xx unknown
- 2013-08-29 CA CA2882316A patent/CA2882316A1/en active Pending
- 2013-08-29 MX MX2015002210A patent/MX2015002210A/es unknown
- 2013-08-29 CN CN201380056438.5A patent/CN104936581A/zh active Pending
- 2013-08-29 RU RU2015111258A patent/RU2015111258A/ru not_active Application Discontinuation
-
2015
- 2015-02-17 IL IL237276A patent/IL237276A0/en unknown
- 2015-02-27 PH PH12015500435A patent/PH12015500435A1/en unknown
- 2015-03-05 IN IN1857DEN2015 patent/IN2015DN01857A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN01857A (enExample) | 2015-05-29 |
| US20150216806A1 (en) | 2015-08-06 |
| EP2890367A4 (en) | 2016-03-30 |
| AU2013308403A1 (en) | 2015-03-05 |
| CN104936581A (zh) | 2015-09-23 |
| RU2015111258A (ru) | 2016-10-20 |
| AU2013308403B2 (en) | 2019-02-07 |
| KR20150046310A (ko) | 2015-04-29 |
| EP2890367A1 (en) | 2015-07-08 |
| BR112015004165A2 (pt) | 2017-07-04 |
| JP2015531770A (ja) | 2015-11-05 |
| HK1212222A1 (en) | 2016-06-10 |
| CA2882316A1 (en) | 2014-03-06 |
| IL237276A0 (en) | 2015-04-30 |
| WO2014032108A1 (en) | 2014-03-06 |
| MX2015002210A (es) | 2015-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500435A1 (en) | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions | |
| AU2018253615A1 (en) | Adeno-associated virus mediated gene transfer to the central nervous system | |
| AR088289A1 (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| BR112014008294A2 (pt) | anticorpo anti c-met e usos do mesmo | |
| MX381456B (es) | Regulador de ph de transduccion. | |
| EA202193044A2 (ru) | Способы лечения таупатии | |
| EA201591740A1 (ru) | Вирусы болезни ньюкасла и их применение | |
| CO6612271A2 (es) | Anticuerpos anti-cd40 | |
| BRPI1012759A2 (pt) | anticorpos biespecíficos que se ligam as proteínas do complemento. | |
| EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| BR112013031892A2 (pt) | anticorpos anti-psgl-1 e seu uso | |
| BR112018017228A2 (pt) | composições e métodos para regeneração do músculo usando prostaglandina e2 | |
| EA201591643A1 (ru) | Варианты пертузумаба и их аналитическая характеристика | |
| BR112013031485A2 (pt) | "anticorpos anti-psl de pseudomonas, seus método de produção e uso na prevenção ou no tratamento de infecção por pseudomonas, polinucleotídeo, 5 vetor, composição farmacêutica, bem como métodos in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais e para aumento de morte opsonofagocítica de p. aeruginosa" | |
| EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| WO2013006449A3 (en) | Anti-properdin antibodies and uses thereof | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| ZA201907613B (en) | Dosage regimes for the administration of an anti-cd19 adc |